2019 update of the American College of Rheumatology– recommended rheumatoid arthritis disease activity measures: comment on the article by England et al

2020 ◽  
Vol 72 (5) ◽  
pp. 736-736
Author(s):  
Roy Fleischmann
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Rheumatoid Arthritis Disease Activity ◽  
American College Of Rheumatology ◽  
Rheumatoid Arthritis Disease ◽  
Activity Measures ◽  
Disease Activity Measures

scholarly journals 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures

2019 ◽  
Vol 71 (12) ◽  
pp. 1540-1555 ◽  
Author(s):  
Bryant R. England ◽  
Benedict K. Tiong ◽  
Martin J. Bergman ◽  
Jeffrey R. Curtis ◽  
Salahuddin Kazi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Rheumatoid Arthritis Disease Activity ◽  
American College Of Rheumatology ◽  
Rheumatoid Arthritis Disease ◽  
Activity Measures ◽  
Disease Activity Measures

scholarly journals Measures of Rheumatoid Arthritis Disease Activity in Australian Clinical Practice

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Andrew Taylor ◽  
Hanish Bagga
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Practice ◽  
Disease Activity ◽  
Disease Process ◽  
Biological Agent ◽  
Rheumatoid Arthritis Disease Activity ◽  
Retrospective Audit ◽  
Rheumatoid Arthritis Disease ◽  
Activity Measures ◽  
Disease Activity Measures

Objectives. To investigate which rheumatoid arthritis (RA) disease activity measures are being collected in patients receiving glucocorticoids, non-biologic or biologic disease-modifying antirheumatic drugs (DMARDs) in Australian rheumatology practice. Methods. A retrospective audit of medical records was conducted from eight rheumatology practices around Australia. Each rheumatologist recruited 30 consecutive eligible patients into the review, 10 of whom must have been receiving a biological agent for rheumatoid arthritis. Disease activity measures and radiographic assessments were collected from each patient's last consultation. For biologic patients, disease activity measures were also collected from when the patient was first initiated on the biological agent. Results. At last consultation, the disease measures that were recorded most often were ESR (89.2%), haemoglobin (87.5%), and CRP (84.2%). DAS28 was infrequently recorded (16.3%). The rate of recording disease activity measures for patients receiving biologic DMARDs decreased over time (mean 27 months). Conclusion. This review has shown inconsistency of RA activity measures being recorded in Australian rheumatology clinical practice. An accurate assessment of the disease process is necessary to effectively target rheumatoid arthritis patients to treat in order to achieve optimal outcomes.

Sign in / Sign up

Export Citation Format

Share Document